BioMarin Pharmaceutical Articles
BioMarin files BLA for Vimizim in USA
2 April 2013
BioMarin acquires Zacharon Pharma for upfront $10 million
8 January 2013
Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse
13 August 2012
BioMarin buys ZyStor - and Pompe drug - in staged deal worth a potential $115 million; moves PKU drug into Ph III
19 August 2010
BioMarin launches LEMS drug Firdapse in European Union; and Genmab gets conditional approval for Arzerra
20 April 2010
Showing 1-7 of 7 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
